Dec. 11, 2008--Orexo confirms the announcement made by ProStrakan Group plc, Orexo's partner for Abstral in Europe and North America, that it has received a Marketing Authorisation from the German regulatory authority, BfArM for Abstral (for breakthrough cancer pain).
The details can be read here.
No comments:
Post a Comment